Interleukin-25 (IL-25) is the only anti-inflammatory cytokine of the IL-17 family, and it has been shown to be efficacious in inhibiting neuroinflammation. Known for its effects on cells of the adaptive immune system, it has been more recently described to be effective also on cells of the innate immune system, namely macrophages. We used a lentiviral-mediated gene therapy approach to deliver IL-25 to the central nervous system (CNS) in two mouse models of neuroinflammation, entorhinal cortex lesion and experimental autoimmune encephalomyelitis. In both, we found that IL-25 gene therapy was able to modulate CNS myeloid cells, either infiltrating macrophages or resident microglia, towards an anti-inflammatory, tissue-protective phenotype, as testified by the increase in markers such as Arginase-1 (Arg1), Mannose receptor 1 (CD206) and Chitinase 3-like 3 (Ym1). As a consequence, neuroinflammation was partly inhibited and the CNS protected from immune-mediated damage. To our knowledge, this is the first example of M2 shift (alternative activation) induced in vivo on CNS-resident myeloid cells by gene therapy, and may constitute a promising strategy to investigate the potential role of protective microglia in neurological disorders.
INTRODUCTION
Interleukin-25 (IL-25), also known as IL-17e, is the only member of the IL-17 cytokine family that exerts anti-inflammatory properties. 1 Produced by several cells, such as Type 2 helper T (Th2) cells, mast cells, epithelial cells, eosinophils, basophils and alveolar macrophages, [2] [3] [4] [5] [6] IL-25 was initially described to modulate Th2 cell function in autoimmune disorders and type 2-cytokine immune diseases, [7] [8] [9] [10] underlining its function in adaptive immune responses. However, recent studies suggest a new role for IL-25 on cells of the innate immune system, for example macrophages.
11-14 IL-25, in fact, protects mice from colitis and proteinuric kidney disease by promoting alternative (M2) macrophage activation and thus inhibiting inflammation in vivo, 11,14 a finding not paralleled by corresponding in vitro data. 15, 16 Despite being extremely plastic in the activation phenotype they can display, macrophages polarize towards two main functional phenotypes, according to activation stimuli. [17] [18] [19] Classical Toll-like receptor agonists, that is, lipopolysaccharide, or pro-inflammatory cytokines, induce a phagocytic, pro-inflammatory (M1) activation state, characterized by the production of IL-1b, tumor necrosis factor alpha (TNFa), inducible nitric oxide synthases (iNOS) and reactive oxygen species; 20, 21 while IL-4 induces alternative (M2) activation, characterized by anti-inflammatory and tissueremodeling functions and the expression of markers such as Arginase-1 (Arg-1), Chitinase 3-like 3 (Ym1), mannose receptor 1 (CD206) and CC chemokine ligand 17 and 22 (CCL17 and CCL22). [22] [23] [24] [25] Microglia are the resident macrophages of the central nervous system (CNS) whose activation is considered a pathological hallmark of several neurodegenerative disorders, such as multiple sclerosis. 20, 26 The M1/M2 paradigm, validated for macrophages, has not really been explored in detail for microglia. However, several lines of evidence suggest that microglia display functional phenotypes that are similar to peripheral macrophages. [27] [28] [29] [30] As pro-inflammatory microglia are considered crucial in the vicious circle leading to neuronal death in classical neurodegenerative disorders, and in the progressive phases of MS, both still lacking efficacious treatment, it is commonly believed that modulation of microglia towards a protective phenotype might be a useful therapeutic strategy for these disorders. [31] [32] [33] [34] [35] IL-25 has been shown previously to inhibit neuroinflammation 9 , and the aim of the present work has been to investigate if IL-25 modulates microglia inducing an anti-inflammatory, protective phenotype. We took advantage of the common previous pioneering experience of our groups in delivering cytokines to the CNS using the so called 'ependymal route'. 36 Briefly, lentiviral vectors engineered to express cytokines are injected in cerebrospinal fluid spaces, infecting ependymal and leptomeningeal cells that, in turn, produce and release the desired cytokine into the cerebrospinal fluid (CSF), thus reaching the entire CNS. [37] [38] [39] [40] [41] [42] Using this gene therapy approach, after in vitro validation of the IL-25-expressing lentiviral vector, we administered IL-25 in two mouse models of neuroinflammation, the entorhinal cortex lesion (ECL) model [43] [44] [45] [46] and experimental autoimmune encephalomyelitis (EAE). 47 We found that IL-25 was indeed able to shift CNS myeloid cells towards an anti-inflammatory phenotype and to inhibit neuroinflammation. This approach to modulate microglia may therefore be useful to investigate their role in physiology and pathology, and constitute an alternative therapeutic approach in diseases where microglia are considered crucial. Figure 1a) . We next ascertained that myeloid cells, in this case bone marrow (BM)-derived macrophages, express IL-17rb, the IL-25 receptor, as shown by confocal fluorescent microscopy in Figure 1b and by fluorescence-activated cell sorting (FACS) staining (data not shown). Finally, we confirmed that IL-25HA activates the appropriate signaling pathway in BM-macrophages by inducing p38 phosphorylation, comparable to recombinant IL-25 (rIL-25) (Supplementary Figure 1b) , and by inducing expression of IL-4, IL-5 and IL-13 messenger RNA (mRNA) in spleenocytes (Figure 1c) , as previously described. 48 After validation of our construct in terms of expression and bioactivity, we next examined its effects on myeloid cells. IL-25HA administered to purified BM-macrophages in culture induced a decrease in the mRNA expression of both M1 (IL-1b and TNF-a) and M2 (CD206) activation markers, together with T-cell-attracting chemokines (CCL2 and CXCL10) and a significant increase of Socs3 mRNA expression, similar to rIL-25 ( Figure 1d ). IL-25 gene therapy induces alternative activation of microglia in an ECL model We next verified if IL-25 was able to inhibit microglia activation in vivo similar to macrophages in vitro. We therefore investigated the effects of IL-25HA, delivered by lentiviral gene therapy, on microglia in the ECL mouse model. In this model, microglia become activated in response to synaptic degeneration following transection of perforant path (PP) axons in the entorhinal cortex 43 ( Figure 2a) . The IL-25HA-expressing lentivirus (lenti-IL-25HA) was delivered by intracisternal (i.c.) injection 5 days before the PP lesioning, as previously described. At 48 h post transection, thus 7 days post lentiviral infection, ependymal and leptomeningeal cells close to the hippocampus, where microglia activation occurs, are infected by this procedure (Figure 2b ). Moreover, we detected efficient IL-25HA mRNA transcription in hippocampi of mice injected with Lenti-IL-25HA (Figure 2c) .
To investigate the functional significance of IL-25 in ECL model, 5 days before PP-axons transection, C57Bl/6 mice were i.c. injected with lenti-IL-25HA or green fluorescent protein (GFP)-expressing lentivirus and killed 48 h post surgical lesion for FACS, real-time reverse transcriptase PCR (RT-PCR) or histological analysis. When we measured the number of infiltrating CD45
þ CD11b þ myeloid cells to the lesion-reactive hippocampi (Figure 3 ), we found, as expected, that synaptic degeneration induced an increase in the number of infiltrating
CD45
high CD11b þ myeloid cells to the lesion-reactive hippocampi of both lenti-GFP-injected control mice and lenti-IL-25HA-injected mice. However, the number of infiltrating CD45 high CD11b þ myeloid cells were significantly higher in the lesion-reactive hippocampi of mice injected with IL-25HA than in control mice ( Figure 3b ). In contrast, IL-25 had no effect on the number of CD45 low CD11b þ microglia or on the synaptic degenerationinduced increase in CD45
high CD11b À TCRb þ T cells as compared with control mice (Figures 3c-d) .
RT-PCR analysis conducted on whole hippocampi showed that, IL-25 induces IL-5 and IL-13 anti-inflammatory cytokines mRNA expression (Figures 4a-c) , as previously demonstrated in in vitro assay. However, in distinction from isolated myeloid cell cultures, M2 activation markers (that is, CD206, Arg-1, YM-1, CCL17 and CCL22; Figures 4c-g ) and, surprisingly, IL-6 ( Figure 4h ) were markedly increased, while M1 activation markers were unaffected (that is, IL-1b, TNF-a and iNOS; Figures 4g-i). Sorting and individual phenotype analysis was not possible owing to the low number of cells isolated from hippocampi. However, we analyzed by confocal microscopy the expression of the M2 marker mannose receptor 1 (CD206) that was increased by RT-PCR, and found it confined exclusively to microglia (Supplementary Figure 2) . Compared with in vitro experiments, these data suggest that induction of M2 alternative activation of microglia in vivo is not dependent on IL-25 signaling in myeloid cells alone.
IL-25 gene therapy induces M2 markers during experimental neuroinflammation Previous work had shown that IL-25 CNS gene therapy inhibits both chronic and relapsing EAE also when administered after disease onset. 9 low /CD11b þ microglia was reduced only in the spinal cord, where there is more inflammation (Figures 6a-d) .
On the contrary, we found no effect of IL-25 gene therapy on relapsing remitting (RR)-EAE. IL-25HA gene delivery does not induce an amelioration of the disease when administered i. 
DISCUSSION
Currently, microglia are believed to have a crucial role in the pathogenesis of several neurological disorders. Translating to microglia the paradigm of pro-inflammatory (M1) or antiinflammatory (M2) alternative activation, validated in peripheral macrophages, it has been hypothesized that in both neurodegeneration and the chronic phases of neuroinflammation alterations in activation state may have a pivotal role. Very little information, however, is available on the functional phenotype of microglia, whether detrimental (M1-like) or protective (M2-like), during human and experimental disease. This is owing to the difficulty in accessing microglia during human disease, and to purify these myeloid cells distinguishing them from infiltrating macrophages in animal models. Further, validated tools to modulate microglia response in one direction or the other in vivo are currently lacking. We believe we have shown here one of the very few successful examples of in vivo modulation of microglia to express markers associated to a protective M2 phenotype.
To this purpose, we exogenously expressed HA-tagged IL-25 from a lentiviral vector. IL-25 had been shown to be effective in neuroinflammation, 9 and we investigated the hypothesis that this beneficial effect might be mediated by microglia. We used two different in vivo models to test the role of IL-25. The first is a model of mild inflammation in the hippocampus obtained by causing anterograde axonal degeneration in the PP by injuring the entorhinal cortex (ECL). The second is a classical model of neuroinflammation, namely EAE. 47 Clinical beneficial effect of IL-25 gene therapy cannot be appreciated in the ECL model and was seen in EAE but only in the chronic model. We do not have an obvious explanation for the discrepancy between our findings and previous data on relapsing EAE, 9 other than that we use more adjuvant in our immunization protocol. From the pathological point of view, however, in ECL we found an increased number of CD45 high CD11b þ cells in the lesion-reactive hippocampi. At the same time, we detected an overexpression of all M2 markers tested in IL-25HA-treated mice, analyzed by RT-PCR. This strongly suggests that IL-25 induces alternative activation in vivo in CNSresident myeloid cells. As we have demonstrated in the past 37 and also in the present series of experiments (data not shown) that cytokines delivered through the ependymal route do not have any effect in the peripheral immune system, we have to assume that the main action of CNS-delivered IL-25 has been exerted on local microglia, rather than on already committed infiltrating macrophages.
In EAE, on the other hand, where the infiltration of the CNS by inflammatory cells is incomparably higher than in ECL, 49 we found a significant decrease of infiltrates in IL-25HA-treated mice, both by FACS and neuropathological analysis. This apparent discrepancy in the two models may be explained by the molecular analysis. When we analyzed the acute phase of EAE, characterized by massive infiltration of macrophages, we found that IL-25 gene Supplementary Figure 3 . In both models, the tissueprotective effect of IL-25HA gene therapy might be related to the release of neurotrophic factor by modulated microglia. We found no induction, however, at the mRNA level, for GDNF, BDNF, IGF-I and TGFb (data not shown). We cannot exclude that other neurotrophins are modulated and may have a role. Why does IL-25 induce an anti-inflammatory profile in myeloid cells in vivo, while it is broadly inhibitory, both on M1 and M2 markers, in vitro? During the in vitro validation, we confirmed, for the first time by confocal microscopy, expression on the membrane of BM-derived macrophages of IL-17RB, the IL-25 receptor, that had previously been shown in mouse by flow cytometry. 13 We found that IL-25 induces Socs3, as was previously described, 15 and inhibits the transcription of pro-and antiinflammatory cytokines in myeloid cells in vitro. We have examined the effect of IL-25 in vitro also on unfractionated splenocytes, obtaining the same results as in purified macrophages showing that the presence of third-party non-macrophage cells makes no difference. Similar in vitro/in vivo discrepancy on macrophages has been reported for IL-25 in a model of colitis. 14 It is tempting to speculate that myeloid cells display in vivo, but not in vitro, a phenotype prone to shift to M2 upon IL-25 stimulation. Further, the inflammatory microenvironment present in EAE may predispose microglia to this shift. This would fit very well with the idea of great plasticity of myeloid cells, keeping a certain functional phenotype by integrating a number of different inputs, most of which are certainly absent in conventional in vitro cultures. There may also be a time issue, as in vivo the time scale is much longer than in in vitro experiments, although we observed the M2 shift in ECL after only 48 h.
Microglia are believed to have a crucial role in the pathogenesis of several neurological disorders, but very little information is available on their functional phenotype during disease. We have shown in the present work one of the very few successful examples of in vivo CNS myeloid cell phenotype modulation with a selected cytokine, namely IL-25, by using our gene therapy approach targeting the CSF. We think this may constitute a useful tool to investigate the role of microglia-activation patterns during neurological disorders and, at the same time, a potential alternative therapeutic approach for CNS diseases in which microglia is believed to have a detrimental role. 0 . Then mIL-25 cDNA was linked to HA-tag by a step cloning into pcDNA3.1 plasmid. A third-generation lentivirus expressing mIL-25HA was generated cloning the mIL-25HA cDNA in the backbone of a p277 lentiviral transfer vector and producing a lentivirus as previously described. 50 A GFP-expressing lentivirus was also produced to be used as negative control in all the in vitro and in vivo experiments.
MATERIALS AND METHODS

Generation of mouse IL-25-expressing lentivirus
IL-25 in vitro production
HEK293T cells were grown in Iscove Modified Dulbecco Medium supplemented with 10% of fetal bovine serum (FBS), 2 mM ultra-glutamin and 100 U ml penicillin/streptomycin (Lonza, Braine-l 0 Alleud, Belgium). Cells were seeded at 50 000 per well in a 6-well plate (Corning Incorporated Life Sciences, Lowell, MA, USA) and, 24 h later, infected by IL-25HA-expressing or GFP-expressing lentivirus (multiplicity of infection ¼ 5). After 48 h, IL-25HA or GFP-conditioned medium were collected and stored at À 80 1C for western blot analysis or BM-derived macrophages in vitro functionality assay. IL-25HA or GFP-infected cells were lysed with a scraper in 300 ml of Lysis Buffer (150 mM NaCl, 1% Triton-X-100, 50 mM Tris HCl pH 8.0) (powders from Sigma, St Louis, MO, USA) for western blot analysis.
BM-derived macrophages in vitro culture
Macrophages were isolated from BM's flushing and cultured with macrophage-colony stimulating factor (100 ng ml À 1 , Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) in a-Minimum Essential Medium (MEM) (Invitrogen) for 7 days. The purity of BM-macrophages' cultures was confirmed by FACS using CD11b (1:100, BD Biosciences, Mountain View, CA, USA) and F4/80 (1:100, BioLegend, San Diego, CA, USA) antibodies. Differentiated macrophages were cultured on coverslip glasses in a-MEM medium (Invitrogen) for 48 h for immunofluorescence studies.
To analyze phosphorylation of p38 protein, differentiated macrophages were incubated with IL-25HA or GFP-conditioned media (in a ratio 1:1, 1:0.5, 1:0.25 to a-MEM) for 30 min. rIL-25 (25-50 ng ml À 1 , R&D Systems, Minneapolis, MN, USA) was used as positive control. Then cells were lysed with a scraper in 100 ml of Lysis Buffer (150 mM NaCl, 1% Triton-X-100, 50 mM Tris HCl pH 8.0) (powders from Sigma) for western blot analysis.
For RT-PCR analysis, differentiated macrophages were cultured with IL-25HA or GFP-conditioned media in a ratio 1:1 to a-MEM for 48 h. rIL-25 (50 ng ml À 1 , R&D Systems) was used as positive control. Then cells were lysed in Trizol (Invitrogen) for RNA extraction.
Immunofluorence studies BM-derived macrophages were post-fixed in paraformaldehyde (PFA) 4% for 10 min and incubated in 5% FBS-PBS1X for 1 h, to block any nonspecific binding site. Primary anti-IL-17rb (1:20, R&D Systems) and anti-F4/80 (1:200, Abcam, Cambridge, MA, USA) antibodies were used to reveal IL-17rb and F4/80 on macrophages. Alexa-fluor secondary antibodies (546 for IL-17rb and 488 for F4/80) from Molecular Probes (Invitrogen) were used.
Sections from lesion-reactive hippocampi of GFP-injected or IL-25HA-injected mice were post-fixed in PFA 4% for 10 min and then incubated in 5% FBS-PBS1X for 1 h, to block any nonspecific binding site. Primary anti-HA (1:1,000, eBioscience, San Diego, CA, USA), anti-Iba1 (1:400, Wako Chemicals USA Inc., Richmond, VA, USA) and anti-CD206 (1:200, BD Biosciences) antibodies were used to stain infected epedymal cells, myeloid cells and IL-17rb, respectively. Alexa-fluor secondary antibodies (1:200; 488 for HA or IL-17rb, 546 for CD206) from Molecular Probes (Invitrogen) were used.
In all the experiments, nuclei were stained with 4 0 6-diamidino-2-phenylindole (1:25 000; Roche Diagnostics Spa, Monza, Italy). Staining omitting the primary antibodies were used as negative control. A Leica (Leica Microsystems, Milano, Italy) confocal microscopy for the acquisitions of pictures was used.
Western Blot
Kit BCA Protein Assay (Thermoscientific, Waltham, MA, USA) was used to quantify proteins in cells' lysates (HEK293T cells, BM-macrophages). Twenty micrograms of proteins from IL-25HA or GFP-infected HEK293T and IL-25HA or GFP-treated BM-macrophages were subjected to SDS (Sigma)-12% PAGE before blotting onto a polyvinylidene difluoride membrane (Whatman, GE Healthcare, Waukesha, WI, USA). Membranes were blocked with 5% skimmed milk in Tris-buffered saline with 0.05% Tween 20 (pH 7.6) (Sigma) for 1 h at room temperature, and probed with primary anti-HA-tag (1:20, eBioscience), anti-bactin (1:30 000, Sigma), anti-p38 and anti-p38 (1:1000; phospho T180 þ Y182) monoclonal antibody (Abcam) for 2 h at room temperature. Membranes were then incubated with secondary peroxidase-conjugated AffiniPure anti-rabbit or anti-mouse IgG (H þ L) antibodies (1:10 000; Jackson Immuno Reaserch, Suffolk, UK) for 1 h at room temperature. Antibody-antigen complexes were then detected using ECL IMMOBILON WESTERN Chemiluminescent HRP-substrate detection system (Millipore, Billerica, MA, USA) according to the manufacturer's instructions.
Mice
For ECL mouse model 8-week-old C57BL/6 wild-type mice were purchased from Taconic (Taconic Europe, Lille Skensved, Denmark). For EAE mouse model 8-week-old C57Bl/6 and SJL wild-type female mice were obtained from Charles River (Calco, Italy). Mice were provided with food and water ad libitum and were housed under pathogen-free conditions with a constant light/dark cycle. All procedures involving animals were performed according to the guidelines of the National Danish Animal Research Committee and to the animal protocol guidelines prescribed by the Institutional Animal Care and Use Committee (IACUC #331) at San Raffaele Scientific Institute (Milan, Italy).
Intracisterna magna injection
Intrathecal injection of lentivirus were performed as described previously 38 at the desired time point. A 30-gauge needle attached to a Hamilton syringe were inserted into the intrathecal space of the cisterna magna of anesthetized mice. IL-25HA-expressing or GFP-expressing lentiviruses (10 ml) in sterile phosphate-buffered saline (10 9 PFU ml
) were injected over 30 s.
IL-25 gene therapy of ECL mouse model C57BL/6 mice received an intra cisterna magna (i.c.) injection of IL-25HA-expressing or GFP-expressing lentivirus (10 ml, 10 9 ml À 1 ) 5 days before perfoming ECL. Under anesthesia, mice were placed in a Kopf stereotactic apparatus (Kopf Instruments, Tujunga, CA, USA) and a burr hole was drilled in the skull 1.9 mm lateral to lambda and 0.3 mm caudal to the lambdoid suture. The nosebar was set at 3 mm. A wire knife (Kopf Instruments) was inserted at an angle of 15 1 rostrally and 10 1 laterally, and 3.4 mm ventral to the meninges, the knife was unfolded and the entorhinodentate PP projection was sectioned by retracting the knife 3.2 mm. 44 Mice were killed 48 h post surgical lesion for real-time PCR, FACS or histological analysis.
IL-25 gene therapy of EAE mouse model
Chronic EAE was induced in female C57BL/6 mice, by subcutaneus with 300 ml of 200 mg per mouse of MOG (Espikem, Florence, Italy) in IFA (Sigma) supplemented with 8 mg ml À 1 Mycobacterium tuberculosis (strain H37Ra; Difco, Lawrence, KS, USA). Pertussis toxin (500 ng, List Biological Laboratories, Campbell, CA, USA) was injected intraperitoneally on the day of the immunization and again 2 days later, as described. IL-25HA-expressing lentivirus or GFP-expressing lentivirus were injected in the cisterna magna (i.c.) of the mice at fifth d.p.i.
RR-EAE was induced in female SJL/j mice, by two subcutaneus injections, 7 days apart, into both flanks with 100 ml of an emulsion containing 200 mg per mouse of PLP 139-151 (Espikem) and 8 mg ml À 1 of heat-killed M. tuberculosis in IFA. In addition, mice received four intraperitoneal injections of 500 ng of Pertussis toxin on the day of immunization and 24 h later, as described. 51 ELISA assay for mIL-25 mIL-25HA was measured in supernatants and lysates of infected cells or CSFs (withdrawn from mice cisterna magna by capillarity) or brain homogenates from IL-25-injected EAE mice, using DUOset ELISA mouse IL-17-E (R&D Systems).
Preparation of CNS mononuclear cells
For ECL and EAE experiments, mice were deeply anesthetized and perfused transcardially with cold phosphate-buffered saline at the indicated time point. For ECL, brains were removed, and controlateral and lesion-reactive (ipsilateral) hippocampi were dissected out and homogenized through a 70 mm cell strainer (BD Falcon, Mountain View, CA, USA) in HBSS (Invitrogen). Mononuclear cells were then washed with cold PBS1X three times and collected by centrifugation for flow cytometric staining.
For EAE, brains and the spinal cords were dissected out at the desired time point, removed and homogenized through a 70-mm cell strainer in HBSS. Mononuclear cells were isolated by 30/37/70% percoll (GE Healthcare) gradient centrifugation and collection of mononuclear cells from the 37/70% interphase.
Abs and FACS analysis
For ECL experiments, cells were stained with the following monoclonal antibodies (all from BD Biosciences): PE-conjugated anti-CD45 (1:400), PerCP-conjugated anti-CD11b (1:100) and allophycocyanin-conjugated anti-TCR (1:200) antibodies to detect microglia/macrophages or T cells, respectively. 53, 54 For EAE experiments, cells were stained with the following monoclonal antibodies (all from BD Biosciences): APC-conjugated anti-CD45 (1:100), APC-Cy7-conjugated anti-CD11b (1:100) and PE-Cy7-conjugated anti-CD3e (1:100) antibodies to detect microglia/macrophages or T cells, respectively. 5000 BD Calibrate Beads were added for sample. Both ECL-and EAEderived cells were all collected on a FACSCanto machine (BD Biosciences) and analyzed using FCSexpress software (De Novo Software, Los Angeles, CA, USA).
Histological evaluation
At least four EAE mice per group were perfused at sixtieth d.p.i. through the left cardiac ventricle with saline, plus EDTA 0.5 M for 10 min followed by fixation with cold 4% PFA (Sigma) in 0.1 M phosphate buffer (pH 7.4). Subsequently, spinal cords and brains from EAE mice were carefully dissected out and post-fixed in 4% PFA overnight and processed for cryogenic embedding. The quantification of neurological damage in EAE mice was performed via histological analysis of 10 mm frozen CNS sections of control or IL-25HA-injected or GFP-injected EAE mice. Three different staining were used to detect inflammatory infiltrates (Hematoxylin and Eosin), demyelination (Luxol fast blue) and axonal damage (Bielshowsky). Neuropathological findings were quantified on an average of 10 complete cross-sections of spinal cord per mouse taken at eight different levels of the spinal cord. The number of perivascular inflammatory infiltrates were calculated and expressed as the numbers of inflammatory infiltrates per mm 2 , demyelinated areas and axonal loss were expressed as percentage of damaged area.
Immunohistochemistry for HA-tag (anti-HA antibody 1:20, eBioscience) was performed to characterize mIL-25HA-positive cells in the lentivirus-infected EAE brain. Labeling was revealed with an appropriate biotin-labeled secondary antibody (1:500, Amersham, Airlington Heights, IL, USA) and developed with the ABC kit (Vector Laboratories, Burlingame, CA, USA) followed by either liquid DAB Substrate Chromogen System (DAKO, Glostrup, Denmark) or Peroxidase Substrate Kit TMB (Vector Laboratories). An Olympus microscope (Olympus, Segrate, Italy) for the acquisitions of pictures was used.
RT-PCR analysis
RT-PCR analyses were perfomed for in vitro BM-derived macrophages assay and for IL-25 gene therapy studies of ECL model or EAE model. Briefly, RNA was extracted in Trizol (Invitrogen). Residual DNA was removed by treatment with 1 U DNase per 1 mg RNA (RQ1 RNase-free DNase, Promega) at 37 1C for 30 min. cDNA synthesis from 3-5 mg total RNA was performed using Ready-To-Go You-Prime First-Strand Beads (Amersham) and Random Hexamer (New England Biolabs, Ipswich, MA, USA) according to the manufacturer's instructions. Arg-1 (Mm00475988_m1), CCL1 (Mm00441236_m1), CCL2 (Mm00441242_m1), CCL17 (Mm005161 36_m1), CCL22 (Mm00436439_m1), CD206 (Mm00485148_m1), CXCL10 (Mm00445235_m1), IFNg (Mm01168134_m1), IL-1b (Mm01336189_m1), IL-4 (Mm00445259_m1), IL-5 (Mm00439646_m1), IL-6 (Mm00446190_m1), IL-10 (Mm00439616_m1), IL-13 (Mm00434204_m1), IL-17 (Mm00439618_m1), IL-25 (Mm00499822_m1), iNOS (Mm00440502_m1), Socs3 (Mm00545913_s1), TNF-a (Mm00443258_m1) and Ym1 (Mm00657889_mH) mRNA levels were measured by real-time RT-PCR (Applied Biosystem, Invitrogen). The 2 À DDCT method was used to calculate relative changes in gene expression. 55 
Statistical analysis
Statistical evaluations of RT-PCR data, ELISA assay, FACS data, EAE score and immunohistochemical analyses results were expressed as mean ± s.e.m. Results were analyzed using the unpaired Student's t-test and Mann-Whitney U-test for samples with unknown and potentially disparate variances. Analyses were performed using the Prism V5.0a software (Graph-Pad, San Diego, CA, USA). Statistical significance was accepted when *Po0.05, **Po0.01, ***Po0.001.
